Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Update

Vivani Medical, Inc. (NASDAQ:VANI) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totaling 532,131 shares, an increase of 65.0% from the March 15th total of 322,575 shares. Based on an average daily trading volume, of 280,776 shares, the days-to-cover ratio is presently 1.9 days. Currently, 1.2% of the shares of the stock are short sold.

Vivani Medical Stock Performance

Shares of Vivani Medical stock traded up $0.02 during midday trading on Tuesday, hitting $1.07. 44,577 shares of the company traded hands, compared to its average volume of 203,053. The stock has a market cap of $90.58 million, a price-to-earnings ratio of -2.49 and a beta of 2.16. The firm’s fifty day moving average price is $1.16 and its 200-day moving average price is $1.33. Vivani Medical has a 12 month low of $0.92 and a 12 month high of $1.92.

Vivani Medical (NASDAQ:VANI) last posted its earnings results on Thursday, March 26th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. Equities research analysts forecast that Vivani Medical will post -0.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on VANI. HC Wainwright decreased their target price on shares of Vivani Medical from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $3.50.

Insider Buying and Selling

In other news, Director Gregg Williams bought 1,737,765 shares of the firm’s stock in a transaction on Thursday, January 15th. The shares were purchased at an average cost of $1.14 per share, with a total value of $1,981,052.10. Following the acquisition, the director directly owned 26,564,109 shares in the company, valued at $30,283,084.26. This represents a 7.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have bought 4,664,347 shares of company stock valued at $5,666,549. 46.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vivani Medical

Hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in Vivani Medical during the 3rd quarter worth approximately $26,000. Susquehanna International Group LLP boosted its position in Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after buying an additional 16,200 shares during the period. Jane Street Group LLC acquired a new stake in Vivani Medical during the 4th quarter worth approximately $60,000. Renaissance Technologies LLC boosted its position in Vivani Medical by 118.4% during the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after buying an additional 53,127 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Vivani Medical during the 4th quarter worth approximately $174,000. 6.78% of the stock is currently owned by institutional investors and hedge funds.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.